Synta Pharmaceuticals Corp.  

(Public, NASDAQ:SNTA)   Watch this stock  
Find more results for SNTA
0.400
-0.021 (-4.99%)
Apr 29 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 0.39 - 0.44
52 week 0.15 - 2.65
Open 0.42
Vol / Avg. 937,734.00/1.42M
Mkt cap 56.18M
P/E     -
Div/yield     -
EPS -0.55
Shares 137.81M
Beta 1.17
Inst. own 18%
Apr 14, 2016
Synta Pharmaceuticals Conference Call to Discuss Definitive Merger Agreement to Acquire Madrigal Pharmaceuticals Inc - Webcast
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '15) 2015
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -53.09% -81.33%
Return on average equity -76.30% -118.87%
Employees 10 -
CDP Score - -

Address

45 HARTWELL AVE
LEXINGTON, MA 2421
United States - Map
+1-781-2748200 (Phone)
+1-781-2748228 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Synta Pharmaceuticals Corp. is a biopharmaceutical company. The Company focuses on research, development and commercialization of oncology medicines for cancer patients. Its lead oncology drug candidate is ganetespib, which is a heat shock protein 90 (Hsp90) inhibitor. The Company also has an additional clinical-stage oncology candidate: elesclomol, which is a mitochondrial metabolism inhibitor. Ganetespib is a small molecule inhibitor of Hsp90, which is a molecular chaperone required for the folding and activation of cancer-promoting proteins. Elesclomol is a first-in-class investigational drug candidate that triggers programmed cell death (apoptosis) in cancer cells through a mechanism: disrupting cancer cell energy metabolism. The Company entered into a license arrangement for its calcium release-activated calcium channel (CRACM) program, including two candidates and the associated intellectual property portfolio, with PRCL Research Inc. (PRCL).

Officers and directors

Keith R. Gollust Chairman of the Board
Age: 69
Bio & Compensation  - Reuters
Chen Schor President, Chief Executive Officer, Director
Age: 42
Bio & Compensation  - Reuters
Marc R. Schneebaum Chief Financial Officer, Senior Vice President
Age: 60
Bio & Compensation  - Reuters
Wendy E. Rieder Esq. Senior Vice President, General Counsel
Age: 47
Bio & Compensation  - Reuters
Scott Morenstein Director
Age: 39
Bio & Compensation  - Reuters
Paul A. Friedman M.D. Independent Director
Age: 73
Bio & Compensation  - Reuters
Bruce Kovner Independent Director
Age: 70
Bio & Compensation  - Reuters
Donald W. Kufe M.D. Independent Director
Age: 70
Bio & Compensation  - Reuters
William S. Reardon CPA Independent Director
Age: 69
Bio & Compensation  - Reuters